Sentences 2 and 3 should read "These characteristics are abstracted into a general formal model ofKBSs.The abstraction levels in this model are illustrated by Figure 2.
Modeling in the design of a KBS validation system
โ Scribed by Henrik L. Larsen; Heri Nonfjall
- Publisher
- John Wiley and Sons
- Year
- 1991
- Tongue
- English
- Weight
- 927 KB
- Volume
- 6
- Category
- Article
- ISSN
- 0884-8173
No coin nor oath required. For personal study only.
โฆ Synopsis
We describe and illustrate the modeling issues in the design of a system for validation o f knowledge based systems (KBSs). The domain of such a validation system i s "KBSs and their validation problems.' The basic idea in our solution i s the following. Since different KBSs may use different knowledge representation languages, we first represent the target KBS (i.e., the KBS to be validated) in a general formal model of KBS. and then validate i t in this form. The advantage of this strategy i s that validation problem solving needs only to refer to the common language o f the general formal model. We present a set o f possible conceptual abstraction levels in such a model, and argue that each level i s associated with a related view on validation problems. Since high level characterizations are difficult to abstract from current knowledge representation languages, we consider the formal aspects of modeling mainly at the "lowest" level, the so-called inference primitive level. We illustrate the approach by formalizing a solution for selected modeling issues at this level.
๐ SIMILAR VOLUMES
This paper discusses the need for formal criteria for the establishment of confidence in, or the ''validation'' of, system dynamics models constructed for fee-paying clients as opposed to for academic research purposes. The meaning of ''validation'' is first considered and the substantial difference
The X-ray structures of pancreatic bovine and porcine phospholipases A2 have been used along with interactive computer graphics to design conformationally rigid, novel compounds (1-meta-hydroxybenzyl-2-substituted acenaphthenes) directed at the active sites of these enzymes. In vitro testing confirm